# Pfs230 domain 12 is a potent malaria transmission–blocking vaccine candidate

## TL;DR

A new malaria vaccine candidate, Pfs230D12, was found to block parasite transmission to mosquitoes, offering a promising approach to stop the spread of malaria.

## Contribution

Pfs230D12 is identified as a potent and novel malaria transmission-blocking vaccine candidate.

## Key findings

- Antibodies against Pfs230D12 reduced parasite transmission in membrane feeding assays.
- D12-specific antibodies also reduced mosquito transmission of parasites from naturally infected carriers.
- Pfs230D12 antigen was recognized by sera from individuals naturally exposed to malaria.

## Abstract

Malaria transmission–blocking vaccines (TBV) target sexual stage parasites that are transmitted to mosquitoes and are critical for spread of the pathogen. The clinically most advanced TBV candidate contains part of the Pro-domain (Pro) and Domain 1 (D1) of Plasmodium falciparum surface protein Pfs230. Subunit vaccines that contain other domains of Pfs230 have so far failed to induce functional antibodies. Here, we produced eight single-domain fragments of Pfs230 in Drosophila melanogaster S2 cells and assessed their immunogenicity in mouse immunizations. In addition to D1-specific antibodies, antibodies raised against D12 showed strong functional transmission-reducing activity in membrane feeding assays with cultured parasites, an activity that was complement dependent. Murine D12-specific antibodies further reduced mosquito transmission of parasites acquired from naturally infected parasite carriers. The D12 antigen was recognized by sera from an all-age cohort of individuals who had been naturally exposed to P. falciparum with antibody levels increasing with age. In conclusion, we identified Pfs230D12 as a promising TBV candidate.

Pfs230D12 is a vaccine candidate inducing antibodies that prevent transmission of malaria parasites to mosquitoes.